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Abstract
Kaposi sarcoma-associated herpesvirus (KSHV) is linked with the development of Kaposi
sarcoma and the B lymphocyte disorders primary effusion lymphoma (PEL) and multi-cen-
tric Castleman disease. T cell immunity limits KSHV infection and disease, however the
virus employs multiple mechanisms to inhibit efficient control by these effectors. Thus
KSHV-specific CD4+ T cells poorly recognize most PEL cells and even where they can,
they are unable to kill them. To make KSHV-infected cells more sensitive to T cell control we
treated PEL cells with the thymidine analogue azidothymidine (AZT), which sensitizes PEL
lines to Fas-ligand and TRAIL challenge; effector mechanisms which T cells use. PELs co-
cultured with KSHV-specific CD4+ T cells in the absence of AZT showed no control of PEL
outgrowth. However in the presence of AZT PEL outgrowth was controlled in an MHC-
restricted manner. To investigate how AZT sensitizes PELs to immune control we first
examined BJAB cells transduced with individual KSHV-latent genes for their ability to resist
apoptosis mediated by stimuli delivered through Fas and TRAIL receptors. This showed
that in addition to the previously described vFLIP protein, expression of vIRF3 also inhibited
apoptosis delivered by these stimuli. Importantly vIRF3 mediated protection from these apo-
ptotic stimuli was inhibited in the presence of AZT as was a second vIRF3 associated phe-
notype, the downregulation of surface MHC class II. Although both vFLIP and vIRF3 are
expressed in PELs, we propose that inhibiting vIRF3 function with AZT may be sufficient to
restore T cell control of these tumor cells.
Author Summary
Kaposi sarcoma-associated herpesvirus (KSHV) can cause disease in humans in the form
of B lymphocyte disorders such as primary effusion lymphoma (PEL) and multicentric
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Castleman disease. Where tested, these are highly resistant to immune control by KSHV-
specific T cells. To investigate how such KSHV-infected cells can be made more sensitive
to T cell control we treated PEL lines with azidothymidine (AZT), which has been shown
to induce sensitivity in such lines to the mechanisms which T cells use to kill targets. We
found this allowed the T cells to control in vitro lymphoma growth. The ability of the T
cells to control PEL cell growth was found to correlate with AZT mediated inhibition of
function of the KSHV protein vIRF3 which we show has the ability to protect cells from
killing by immune effector mechanisms. These studies suggest that the therapeutic drug
AZT may be of use to tip the virus host balance away from the virus by interfering with
this immune evasion and pro-survival protein, potentially allowing better control by the
host.
Introduction
Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic human γ-herpesvirus which
infects endothelial cells and establishes a latent infection in B lymphocytes. It is associated with
the endothelial cell malignancy Kaposi sarcoma (KS) and the B lymphocyte disorders primary
effusion lymphoma (PEL) and multi-centric Castleman disease (MCD)[1]. The immune
response is important in controlling infection and disease caused by KSHV as seen by the
higher frequency of KSHV-associated disease found in immunosuppressed patients such as
HIV or transplant patients[2]. Restoration of immune competence in KS patients can lead to
resolution of this malignancy [3,4], implying an important role for the cellular immune
response in the control of KSHV-infection and disease.
To control KSHV-malignancies the cellular immune response must overcome immune
evasion mechanisms employed by the virus. These include the production of a restricted reper-
toire of proteins, limiting the range of immune targets but allowing establishment of a pre-
dominantly latent non-virus productive infection. Proteins expressed within KSHV
malignancies include the genome maintenance protein LANA, a cyclin D homologue vCyclin,
an NF-κB activator with pro-survival function vFLIP, and the Kaposin proteins of which the
best characterized, Kaposin B, functions to stabilize cytokine mRNAs (for review see Schulz
and Cesarman[5]). Some of these genes show intrinsic features which likely minimize expo-
sure to CD8+ T cells by restricting synthesis of their encoded protein, reducing the supply of
defective ribosomal products (DRiPs) that are thought to be the source of CD8+ T cell pep-
tide-epitopes[6]. Firstly vFLIP utilizes inefficient codons resulting in the production of unsta-
ble mRNA and low levels of protein expression[7]. Secondly LANA encodes extensive repeat
sequences which restrict translation and proteasomal mediated destruction[8], minimizing
epitope presentation from this protein to CD8+ T cells[9]. KSHV B cell pathologies addition-
ally express an interleukin-6 homologue vIL-6, and the multifunctional protein vIRF3.
Amongst other functions, vIRF3 can inhibit p53 and IRF5 function[10,11] as well as decrease
surface MHC class II expression through inhibiting the promoter of the class II transcriptional
transactivator CIITA[12]. Additionally, infected B cells express the ubiquitin ligases K3 and
K5, which induce endocytosis of surface MHC class I and co-stimulatory molecules such as
ICAM and CD86[13,14]. These multiple layers of immune evasion mechanisms represent a
challenge for T cell mediated control of infected cells.
Studies using CD8+ T cells to probe recognition of PELs expressing reporter antigens have
shown that they were unable to recognize these targets[15]. Recognition of PELs by LANA-
specific CD4+ T cells, which would be less affected by the restricted production of this protein
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as CD4 epitope generation is not reliant on the DRiP pathway, is also mostly poor[16]. This is
likely due to vIRF3 expression as PELs which either constitutively[16] or transiently[17]
express reduced levels of vIRF3 have increased levels of surface MHC class II and can be recog-
nized by the T cells. However in these cases or when vIRF3 function is bypassed and expres-
sion of class II is restored to allow recognition of PELs by LANA-specific CD4+ T cells, these
effectors are not able to kill PELs despite killing other target cell types in parallel assays[16].
Consistent with this finding is that PEL lines are highly resistant to cell death induced by effec-
tor mechanisms that T cells employ, namely stimulation via the extrinsic apoptotic pathways
through Fas or TNF-related apoptosis inducing ligand (TRAIL) receptors[18,19].
The finding that knock down of vFLIP induced sensitivity to Fas ligation indicates that this
viral protein can interfere with this apoptotic pathway[18], however vFLIP is thought to be
expressed at low levels within infected cells[7]; whether other viral proteins contribute to this
inhibition is unclear. An understanding of whether other latent proteins inhibit pathways
induced by extrinsic apoptotic stimuli would allow the rational design of interventions to
inhibit these functions and restore sensitivity to T cell effector mechanisms. Nevertheless some
chemotherapeutic approaches to increase sensitivity of PEL cells to immune clearance have
been developed. In particular, treating PEL cell lines with the thymidine analogue azidothymi-
dine (AZT) renders them sensitive to Fas-ligand or TRAIL mediated killing [19,20]. Addition-
ally AZT has been used therapeutically in combination with IFNα to induce TRAIL expression
in PELs, resulting in their apoptosis [21]. AZT treatment of PELs induces some cleavage of cas-
pase 3 [19] and its mechanism of action has been linked to reducing nuclear translocation of
NF-κB. Specifically the mono-phosphorylated form of AZT has been found to inhibit in vitro
IKKβ-mediated phosphorylation of the NF-κB regulator IκBα [21]. However compared to
other NF-kB inhibitors AZT has a more subtle effect on PELs, not obviously altering growth
or apoptosis, while classic inhibitors such as BAY 11–7082 or Bortezomib rapidly induce apo-
ptosis[22,23].
As T cells are likely to express Fas-ligand or TRAIL, we determined whether KSHV-specific
CD4+ T cells could inhibit the outgrowth of MHC matched AZT-treated PEL lines and found
that this treatment induced sensitivity of PELs to T cell control. We also identified that in addi-
tion to vFLIP, expression of vIRF3 prevented apoptosis induced by extrinsic pathways and that
AZT treatment inhibited this vIRF3 mediated protection.
Results
AZT treatment of PEL cells induces sensitivity to KSHV-specific CD4+ T
cells
We have previously found that KSHV-specific CD4+ T cells poorly recognize most MHC-
matched PEL cell lines, as few PEL cells only transiently express surface MHC class II at any
one time [17]. Engineering PELs to express surface MHC class II allowed recognition but not
killing by the T cells, despite these effectors killing other targets in parallel assays [16]. Cultur-
ing PELs in the thymidine analogue azidothymidine (AZT) induces sensitivity to apoptosis
mediated by Fas-ligand and TRAIL [19,20] and as these can be expressed by T cells, we asked
whether AZT would sensitize PELs to control by KSHV-specific CD4+ T cells.
We initially determined whether a panel of established KSHV-specific CD4+ T cell clones
[16] (Table 1) expressed Fas-ligand and TRAIL transcripts by qRT-PCR analysis after stimula-
tion with autologous target cells sensitized with their cognate peptide-epitope. Transcript
expression was estimated and the levels detected shown in Table 1, expressed relative to those
seen in peripheral blood mononuclear cells (PBMC) activated with phorbol myristate acetate
and ionomycin to induce transcription of these genes[24,25]. Compared to activated PBMC,
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the clones expressed Fas-ligand or TRAIL transcripts in most cases at similar levels to activated
PBMC.
We next developed an in vitro assay to test the ability of KSHV-specific CD4+ T cells to
control outgrowth of MHC-matched AZT-treated PEL lines. Here T cells were co-cultured
with PELs for ten days so all PELs would likely transiently express MHC class II at some time
during the assay, allowing T cell recognition. PELs were grown in 10 μg/ml AZT, which did
not lead to any consistent changes in latent gene expression across the PELs as judged by
qRT-PCR analysis (S1A Fig). Additionally little if any inhibition of proliferation of PELs was
seen when cultured in the presence of AZT (S1B Fig) as previously described [19]. Doubling
dilutions from 10 000 PELs were seeded as triplicate microcultures in 96 well plates and 10 000
MHC-matched KSHV-specific CD4+ T cells were added to each replicate. To act as controls
PELs were either sensitized with the T cells cognate peptide-epitope, or challenged with MHC-
mismatched T cells to assess non-specific inhibition of PEL growth. Additionally, dilutions of
PELs were seeded in the absence of T cells to monitor any growth inhibition from AZT. Iden-
tity of the outgrowing cells was determined by flow cytometry analysis, staining for CD138
and CD4 expression as markers of PELs or T cells respectively. Fig 1 shows representative
results of an assay using the PEL VG-1 and DP-1 restricted, LANA-encoded
LAPSTLRSLRKRRLS-specific CD4+ T cells; T cells are subsequently identified by the first
three amino acids of their cognate peptide-epitope. Microscopic images presented in Fig 1A
show representative results of assays conducted and indicate that there was substantial growth
of cells under some conditions but not others. Thus PELs cultured in the absence of T cells
showed little or no outgrowth inhibition in the presence or absence of AZT. Co-cultures of
PELs with T cells showed that in the absence of AZT there was substantial cell growth; it
would seem unlikely that the cells proliferating here would be the T cell clones as these require
high levels of cytokines to proliferate. Indeed flow cytometry analysis of these populations pre-
sented in Fig 1B (left hand panels) confirmed that they were dominated by CD138 positive
PEL cells and that no additional control of outgrowth was seen when PELs had been sensitized
with epitope-peptide. Parallel assays conducted in the presence of 10 μg/ml AZT, as shown in
Fig 1A (right hand panels), showed cell outgrowth when MHC-mismatched T cells were co-
cultured with PELs. However no obvious outgrowth of cells was seen in co-cultures of VG-1
with MHC-matched LAP-specific T cells in the presence of AZT; furthermore flow cytometry
analysis confirmed that only CD4+ T cells could be detected in these wells (Fig 1B right hand
panels). Importantly, PEL outgrowth was controlled even when they were not sensitized with
the peptide-epitope, implying there was sufficient recognition of the endogenously processed
and presented epitope to allow control.
Table 1. Characteristics of KSHV-specific CD4+ T cells.
Protein Amino acid
location*
Peptide sequence Restriction Functional avidity
(M)
TRAIL
expression†
Fas ligand
expression†
LANA 191–205 LAPSTLRSLRKRRLS DP1 10−8 0.83 0.83
LANA 196–210 LRSLRKRRLSSPQGP DR13 10−6 1.11 1.46
LANA 191–210 LAPSTLRSLRKRRLS/
LRSLRKRRLSSPQGP
DQ6 10−8 3.57 0.28
LANA 66–80 GSPTVFTSGLPAFVS DQ7 10−7 0.1 0.77
vCyclin 41–55 TFQQSLTSHMRKLLG DQ6 10−7 0.78 1.23
*Coordinate location based on BC-1 KSHV sequences
†Transcript level expressed relative to activated PBMC
doi:10.1371/journal.ppat.1006042.t001
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Fig 2 shows averaged results of outgrowth assays graphed as the number PEL cells seeded
required to outgrow T cells. Here the PEL cell lines VG-1, BCBL-1 and JSC-1 were assayed on
at least two occasions with a total of five different MHC-matched CD4+ T cell clones specific
for vCyclin or LANA epitopes. In all cases, assays conducted without AZT showed no T cell
control of PEL outgrowth, regardless of whether the PELs had been pre-sensitized with the T
cell’s peptide-epitope. However parallel assays using MHC-matched T cell clones showed that
in the presence of 10 μg/ml AZT, PEL growth could be inhibited and in some cases completely
controlled. By contrast, culturing MHC-mismatched T cell clones with AZT treated JSC-1
showed some control of these PELs while VG-1 or BCBL-1 showed little or no growth inhibi-
tion when cultured with mismatched clones indicating the specificity of T cell control. Of
note, the inhibition of outgrowth appeared relatively slow. Control of PEL outgrowth took
several days, even in the case of BCBL-1 where all cells expressed surface class II. Thus VG-1
cells cultured with AZT assayed versus LAP- or LAP/LRS-specific clones were ultimately
completely controlled by these effectors, while TFQ-specific cells showed increased control
over background. LRS-specific clones showed the lowest increase in control of non-peptide
Fig 1. Outgrowth assays of PEL cells challenged with KSHV-specific T cells in the presence or absence of
AZT. (A). VG-1 PELs which had been treated with 10 μg/ml AZT for at least one week were either pre-sensitized with
LAP-peptide or not and seeded in triplicate cultures at doubling dilutions from 104 cells per well to 1 250 cells per well.
To these, 104 MHC-matched LAP-specific CD4+ T cells or mismatched CD4+ T cell clones were added and, where
indicated, AZT added to a final concentration of 10 μg/ml. Cultures were allowed to grow for 10 days and cell pellets
then visualized by microscopy. Images show representative cultures of triplicate wells. (B). Flow cytometric
phenotyping of cell populations present at day 10. Cells from the wells highlighted with the black outline in Fig 1A were
stained for expression of CD138 or CD4 and analyzed by flow cytometry.
doi:10.1371/journal.ppat.1006042.g001
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sensitized VG-1 cells with AZT compared to the MHC-mismatch cells which may reflect their
lower functional avidity (10−6 M; Table 1) however sensitizing the PELs with LRS peptide
increased control by these T cells. Similar results were observed using the BCBL-1 and JSC-1
PELs, assayed against appropriately matched T cells. Additionally we confirmed that T cells
pre-treated with AZT showed equivalent control in outgrowth assays (S2 Fig). These findings
indicate that most KSHV-specific T cells recognize sufficient epitope derived from the endoge-
nously expressed protein to induce effector function in these longer term assays and that AZT
sensitizes PEL cells to T cell control.
To better understand the mechanism of T cell control in the outgrowth assays we examined
the PELs for expression of apoptotic cell death markers during the assays. Here BCBL-1 cells
were cultured either with or without AZT and parallel cultures challenged with DQ6-matched
TFQ-specific or MHC-mismatched T cells. After five days PELs were stained with Annexin V
to detect phosphatidylserine as a marker of apoptosis and propidium iodide (PI) to measure
membrane integrity. Fig 3 shows representative flow cytometry plots of one of three assays and
the percentage dead cells was estimated as the combined percentage of cells expressing
Fig 2. Summaries of PEL outgrowth assays after challenge with KSHV-specific CD4+ T cells in the
presence or absence of 10 μg/ml AZT. Cell outgrowth at day 10 was scored after confirming cell identity by
flow cytometry for the indicated PEL and T cell combinations. Data is expressed as the minimum number of
PELs seeded which successfully outgrew the T cells and the dashed line represents the number of AZT
treated PELs seeded in the absence of T cells to achieve outgrowth. Results shown are averages from at
least two assays with error bars representing the standard error of the mean. Black arrowheads indicate
greater than 104 PELs were required to outgrow the T cells.
doi:10.1371/journal.ppat.1006042.g002
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Annexin V and/or PI. BCBL-1 cells cultured without T cells showed 6.2% dead cells and paral-
lel cultures in AZT containing media showed a small increase to 10.8%. BCBL-1 cultured with
MHC-mismatched T cells showed 8.1% dead cells while parallel assays conducted with AZT
showed an increase to 16.2%. Assaying the MHC-matched TFQ-specific T cells against non-
treated BCBL-1 showed some increase compared to the controls with 16.4% dead cells. How-
ever PELs cultured in AZT used in parallel assays with these effectors showed increased cell
death with 47.3% dead cells. These studies indicate that the induction of apoptosis in the PELs
correlates with the control of outgrowth of these cells.
Expression of vFLIP and vIRF3 inhibits apoptosis from Fas and TRAIL
receptor stimuli
We next sought to understand how AZT sensitized PELs to T cell control. The ability of
KSHV-specific CD4+ T cells to kill targets such as Epstein-Barr virus (EBV) transformed B
cells but not PELs [16] led us to hypothesize that a KSHV expressed gene was responsible for
the protective effect and AZT was influencing its function. vFLIP has been shown to have anti-
Fig 3. Apoptotic marker status of PELs co-cultured with KSHV-specific CD4+ T cells. BCBL-1 cells
were either non-treated or cultured in 10 μg/ml AZT and challenged with MHC-matched TFQ-specific or MHC-
mismatched CD4+ T cells. After five days the status of PELs binding Annexin and PI was determined by flow
cytometric analysis.
doi:10.1371/journal.ppat.1006042.g003
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apoptotic function, however its low level of expression in PELs led us to examine whether
other latent proteins may protect from apoptosis mediated by T cell effector mechanisms such
as Fas or TRAIL receptor stimulation. Here genes encoding the PEL expressed proteins
LANA, vCyclin, vFLIP, Kaposin B, vIRF3 and vIL-6 or a control empty construct were cloned
into lentiviral vectors which express transgenes in a tetracycline regulated manner and BJAB
cells transduced with the individual lentivirus constructs. Transgene expressing cells were then
assessed for sensitivity to apoptotic killing through Fas-ligand and TRAIL receptor engage-
ment. BJAB cells were used as they are of B cell origin and sensitive to killing through these
pathways.
We first confirmed transgene expression in the BJAB cells after induction for 24 hours by
western blot analysis of lysates from the cells (Fig 4A). LANA was expressed but showed a
reduction in molecular weight compared to BCBL-1. Nucleotide sequence analysis indicated
this construct was the same as the KSHV-BAC36 sequence from which it was derived, which
in turn was established from BCBL-1. Why it has an apparent lower molecular weight in BJAB
Fig 4. Latent KSHV transgene expression in lentivirus transduced BJAB cells. (A). Transgene
expression was induced by addition of the tetracycline analogue doxycycline (Dox) to BJAB cells transduced
with individual lentiviruses encoding the indicated KSHV genes. After 24 hours lysates were prepared from
these and the PEL BCBL-1, for comparison, which were subjected to western blot analysis. Blots were probed
with antibodies either specific to LANA, vCyclin, vFLIP or vIRF3. (B). vIL-6 expression in transduced BJAB
cells was induced and after 24 hours RNA extracted from these and BCBL-1 cells. vIL-6 and GAPDH
transcripts were estimated from cDNA and vIL-6 transcript abundance expressed relative to GAPDH. Error
bars represent the standard error of the mean.
doi:10.1371/journal.ppat.1006042.g004
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cells is unclear but may relate to differences in post translation modifications of proteins by
BJAB compared to BCBL-1. vCyclin and vFLIP were expressed at markedly higher levels in
transduced BJAB cells compared to BCBL-1, while vIRF3 expression was increased compared
to BCBL-1. We were unable to detect protein expression of Kaposin B so no further analysis
was conducted with these cells. vIL-6 protein could not be detected either in the BJAB or
BCBL-1 cells, however using a previously validated qRT-PCR assay[14] we detected vIL-6 tran-
script at levels similar to those seen in BCBL-1 (Fig 4B).
We next induced expression of the KSHV transgenes in the BJAB cells for 24 hours then
challenged these with agonistic anti-Fas antibody or recombinant TRAIL for 48 hours, as used
previously [19]. Cell death was measured as the combined percentage of cells binding Annexin
V and/or staining with PI. Fig 5A shows representative FACS profiles of induced BJAB cells
either unchallenged or exposed to anti-Fas antibody. Control cells showed induction of cell
death upon challenge, whilst vFLIP or vIRF3 expressing BJAB showed attenuation of death.
Fig 5B and 5C show averaged results from at least five independent assays of the transgene
expressing cells challenged with two concentrations of anti-Fas or TRAIL. For each concen-
tration of the apoptotic stimulus used, significant differences in mean values across the
groups were tested for by one way ANOVA analysis and significant differences between
groups identified by Tukey’s Honest Significant Difference test. Anti-Fas antibody induced
high levels of death in control transgene expressing BJAB cells, while those expressing vIL-
6, LANA and vCyclin showed no significant difference in the percentage of dead cells com-
pared to control cells when challenged with 0.15 μg/ml or 0.075 μg/ml of anti-Fas antibody
(p0.2248 and p0.1642 respectively). However BJABs expressing vFLIP or vIRF3 showed
significantly reduced frequencies of dead cells after challenge with either concentration of
anti-Fas antibody compared to control BJAB (vFLIP p = 5.6x10-4 and p = 4x10-7 or vIRF3
p = 2.6x10-4 and p = 4.1x10-6 for each concentration of anti-Fas). Similar challenge of con-
trol transgene expressing BJAB cells with either 0.1 μg/ml or 0.05 μg/ml TRAIL induced cell
death while expression of vCyclin or vIL-6 gave no protection and LANA showed some
decrease, although none of these values were significantly different to control cell death
(p0.6164 and p0.3182 respectively for each concentration). However significant in-
hibition of cell death was again seen in vFLIP or vIRF3 expressing BJAB after challenge
with either concentration of TRAIL compared to the control cells (vFLIP p<1x10-7 and
p = 2x10-4 or vIRF3 p = 5x10-7 and p = 0.0027 for each concentration of TRAIL). These find-
ings suggest that in addition to vFLIP, vIRF3 has the potential to inhibit apoptosis induced
through Fas and TRAIL pathways.
AZT inhibits vIRF3 mediated protection from cell death
We next determined whether AZT treatment of vFLIP or vIRF3 expressing BJAB cells restored
sensitivity to anti-Fas or TRAIL challenge. Here control, vIRF3 and vFLIP BJAB cells were
grown in media containing 10 μg/ml AZT for at least seven days, which did not obviously
affect their growth (S3 Fig), and transgene expressing cells challenged with anti-Fas or TRAIL
as before. Fig 6 shows data from at least seven independent assays; note a second more potent
batch of anti-Fas antibody was used which induced higher levels of apoptosis. Compared to
untreated control BJABs, AZT treated control BJABs showed non-significant increases in the
percentage of dead cells when challenged with either concentration of anti-Fas (p = 0.99 and
p = 0.99) or TRAIL (p = 0.94 and p = 0.41). vFLIP expressing BJABs as before showed protec-
tion upon challenge with these stimuli compared to control cells, while comparison of
untreated vFLIP expressing to vFLIP expressing cells cultured in AZT showed small non-sig-
nificant increases in the percentage of dead cells upon challenge with both concentrations of
AZT Sensitizes PELs to KSHV-Specific CD4+ T Cell Control
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Fig 5. Cell death induced in BJAB cells expressing KSHV latent genes challenged with anti-Fas
antibody or TRAIL for 48 hours. (A). Representative flow plots of Annexin and PI staining assays.
Transgene expression in BJAB cells was induced for 24 hours and these then challenged with anti-Fas
AZT Sensitizes PELs to KSHV-Specific CD4+ T Cell Control
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anti-Fas (p = 0.98 and p = 0.99) or TRAIL (p = 0.28 and p = 0.91). BJAB expressing vIRF3
again showed protection from challenge with anti-Fas or TRAIL compared to control trans-
gene expressing cells. However parallel cultures of vIRF3-expressing BJABs treated with AZT
had significantly more dead cells compared to non-treated vIRF3 expressing cells when chal-
lenged with both concentrations of anti-Fas (p = 0.0034 and p = 0.0014) or TRAIL (p<1x10-7
and p = 0.0027). These results indicate that in this system, AZT inhibits vIRF3 mediated pro-
tection from anti-Fas and TRAIL challenge.
antibody or TRAIL for 48 hours. Cells were then stained with Annexin and PI, before being analyzed by flow
cytometry. Representative flow plots are shown for induced BJABs with the control transgene either
unchallenged or exposed to anti-Fas antibody, as well as induced vFLIP and vIRF3 transduced BJABs
exposed to anti-Fas antibody. (B). Averaged results of at least five assays where transgene expressing cells
were challenged with either 0.15 μg/ml or 0.075 μg/ml anti-Fas antibody and after 48 hours the percentage of
dead cells binding Annexin with or without PI staining assessed (% Dead). Error bars represent standard error
of the mean. (C). Averaged results of at least five assays where transgene expressing cells were challenged
with either 0.1 μg/ml or 0.05 μg/ml TRAIL for 48 hours and the percentage dead cells estimated as in (B).
doi:10.1371/journal.ppat.1006042.g005
Fig 6. Cell death induced in BJAB cells expressing control, vFLIP or vIRF3 transgenes in the
presence or absence of 10 μg/ml AZT after challenge with anti-Fas antibody or TRAIL. Averaged results
of at least seven assays where control, vFLIP or vIRF3 transduced cells were grown either with or without
10 μg/ml AZT, transgene expression induced for 24 hours and cells challenged with either anti-Fas antibody
or TRAIL and after 48 hours the percentage of dead cells binding Annexin with or without PI staining was then
assessed.
doi:10.1371/journal.ppat.1006042.g006
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To probe the effectiveness of AZT inhibition of vIRF3 protection from apoptotic challenge,
we titrated the concentration of AZT that the vIRF3 and control transgene expressing BJAB
cells were cultured in and then challenged these cells with anti-Fas antibody. Fig 7 shows com-
piled results of three assays measuring the percentage of dead cells 48 hours after challenge. As
before, vIRF3 expressing cells treated with 10 μg/ml AZT lost their protection from apoptosis
induction as did those treated with 5 μg/ml AZT. However concentrations of AZT at 2 μg/ml
or less gave no inhibition of vIRF3 protection.
AZT treatment interferes with other vIRF3 phenotypes in PELs
The ability of AZT to inhibit vIRF3 protective function led us to examine whether AZT treat-
ment altered expression of this protein in the PEL lines. Here lysates from PELs which had been
used in outgrowth assays and either treated with 10 μg/ml AZT or not were made and subjected
to western blot analysis for vIRF3 levels. Fig 8A displays one representative blot of three, show-
ing vIRF3 or actin levels in BCBL-1, JSC-1 and VG-1 cells while Fig 8B shows compiled fold
change in vIRF3 expression from the three assays. AZT treatment of BCBL-1 and VG-1 induced
small if any changes in vIRF3 levels while some decreased expression was seen in AZT treated
JSC-1 cells. These results indicate that AZT treatment can reduce vIRF3 protein levels in some
PEL lines but not others, suggesting its mechanism of action may be through reduction of
vIRF3 levels in some lines but potentially through inhibiting vIRF3 function in others.
We finally investigated whether AZT interfered with other vIRF3 functions by examining a
second phenotype associated with its expression, namely modulation of surface MHC class II
expression on PEL cells [12]. As shown in Fig 9 treatment of BCBL-1 with AZT, which consti-
tutively expresses high levels of surface MHC class II [16], did not alter expression. However
the PELs JSC-1 and VG-1, which constitutively express low levels of surface class II, when
treated with AZT showed increased proportions of cells expressing MHC class II. These stud-
ies are consistent with AZT treatment interfering with vIRF3 function.
Discussion
This work was prompted by our observations that although KSHV-specific CD4+ T cells could
recognize PELs expressing MHC class II [17] or PELs engineered to express surface class II,
they were unable to control them despite killing other cell types [16]. To make PELs more sen-
sitive to T cell control, we treated PELs with AZT and found that LANA- and vCyclin-specific
Fig 7. Titration of AZT inhibition of vIRF3 function in BJAB cells. vIRF3 and control transduced BJAB
cells were cultured in different concentrations of AZT and then transgene expression induced after which the
cells were challenged with anti-Fas antibody and the percentage dead cells determined as in Fig 5. Results
are averages of three independent assays with error bars representing the standard error of the mean.
doi:10.1371/journal.ppat.1006042.g007
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CD4+ T cells inhibited or completely controlled the outgrowth of PELs in co-culture assays.
The inhibition observed in these assays was equivalent or more efficient than that seen in simi-
lar assays using CD4+ T cells specific for latent epitopes from the related human γ-herpesvirus
EBV to control outgrowth of EBV-transformed B cells [26].
To identify how AZT induced sensitivity to T cell control we hypothesized that it was inter-
fering with pro-survival KSHV-gene functions which inhibit cell death pathways initiated by T
cell recognition, namely those of the extrinsic apoptotic pathway. Such KSHV gene products
would include vFLIP which can inhibit killing via Fas [27,28] and a second receptor mediated
killing mechanism, TNF-α [29]. Consistent with these studies we found that expression of
vFLIP in BJAB cells inhibited killing by anti-Fas antibody and TRAIL. Unexpectedly we found
that expression of vIRF3 also inhibited apoptosis induced by these two mechanisms. vIRF3 is a
polyfunctional protein which subverts numerous host pathways, some of which are linked to
apoptosis. Thus knockdown of vIRF3 in PELs induces growth arrest, caspase 3 activation and
apoptosis [30]. vIRF3 has further been reported to bind and inhibit p53 function [10], and
bind to the forkhead box class O (FoxO) 3a transcription factor and its regulatory 14-3-3 pro-
teins. This causes retention of FoxO factors in the cytoplasm, preventing their ability to induce
expression of proapoptotic proteins such as Bim [31]. However these mechanisms would seem
unlikely to intersect with the extrinsic apoptotic pathways triggered in our study. vIRF3 has
also been shown to interfere with apoptosis induced by overexpression of the interferon
induced dsRNA-activated protein kinase R [32], which is known to require the FADD/caspase
pathway for apoptosis induction. However it is not thought that interactions through receptors
such as Fas are responsible for cell death induction in this situation [33]. Our study suggests
that vIRF3 inhibits the extrinsic apoptotic pathway using a different mechanism to those so far
described.
The ability of vFLIP and vIRF3 to protect BJAB cells from extrinsic apoptotic stimuli led us
to examine whether AZT treatment restored sensitivity to these stimuli and we found that
while vFLIP expressing BJAB remained resistant, vIRF3 expressing cells became sensitive. This
Fig 8. vIRF3 levels in AZT treated PEL lines. A. BCBL-1, JSC-1 and VG-1 PELs were either treated with
10 μg/ml AZT or not, lysates made from the lines and subjected to western blot analysis, probing for vIRF3 or
actin expression. One representative blot of three is shown. B. Average fold change of vIRF3 expression was
determined by estimating relative levels of vIRF3 compared to actin in pairs of PELs either treated with or
without 10 μg/ml AZT and the ratio of vIRF3 expression between the pairs determined. Error bars represent
the standard error of the mean.
doi:10.1371/journal.ppat.1006042.g008
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result was surprising as vFLIPs pro-survival function is thought to be mediated through its
ability to activate NF-κB through the canonical pathway by interacting with the IκB kinase
(IKK) complex [34] and AZT is believed to inhibit IKK mediated phosphorylation of IκB [21].
One may have predicted then that AZT would affect vFLIP function, however vFLIP can also
activate the alternative NF-κB pathway [35] and whether AZT can inhibit this pathway is
unknown. Regardless of this, the current experiments indicate that AZT can affect pathways
manipulated by KSHV in addition to NF-κB. The inhibition of vIRF3 mediated protection
from apoptosis by AZT suggests that either AZT alters a cellular pathway that vIRF3 interacts
with, or AZT may act more directly on vIRF3 itself. Support for the latter possibility comes
from our observations that culturing the low class II expressing JSC-1 and VG-1 PELs in AZT
increased surface MHC class II expression on a subset of cells. This finding is consistent with
the drug inhibiting vIRF3 function, preventing repression of CIITA expression, restoring
some degree of MHC class II transcription [12]. Additionally in this context, we believe it is
unlikely that increased expression of surface class II itself is sufficient for T cell control of PEL
outgrowth as BCBL-1 cells express relatively high levels of surface class II and can be recog-
nized by CD4+ T cells [16], yet in the absence of AZT are not controlled by the T cells.
Fig 9. Surface expression of MHC class II on PELs treated with AZT. BCBL-1, JSC-1 or VG-1 PEL cells
were cultured in either normal medium (No AZT) or medium supplemented with 10 μg/ml AZT for at least 10
days, then stained with MHC class II-specific antibodies or an isotype control and analyzed by flow cytometry.
Data is representative of three assays.
doi:10.1371/journal.ppat.1006042.g009
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Furthermore we have previously found that inducing expression of CIITA in PELs, which con-
sequently upregulates surface class II expression, allows recognition by KSHV-specific CD4+
T cells but not killing of these tumor cells [16].
Although we have demonstrated a role for AZT in inhibiting vIRF3 function, we can not
exclude that this drug also alters function of the CD4+ T cell clones used in our assays. How-
ever murine T cells treated with similar concentrations of AZT maintain their cytotoxic func-
tion when cultured in AZT containing medium [36]. Similarly human PBMC maintained in
lower concentrations of AZT compared to the present study also show no obvious difference
in cytokine secretion after stimulation with phytohaemagglutanin or anti-CD3 [37]. Neverthe-
less AZT treatment of PBMC is known to be toxic to mitochondria within T cells or induce
apoptosis in these cells [38], and may reduce their proliferative potential after stimulation with
anti-CD3 [39]. However in the outgrowth assays conducted here we would expect to see little
proliferation of the T cells in the cytokine poor environment of these experiments.
The protection afforded by vFLIP and vIRF3 in BJAB cells upon anti-Fas or TRAIL chal-
lenge suggests both may contribute to protection from such challenges in PELs and potentially,
inhibition of one may be compensated for by the other. Assigning the contribution of either
viral product to protection from apoptotic stimuli may be assessed through using CRISPR/
Cas9 mediated genome editing to establish PEL lines lacking either of these genes, as used to
manipulate other herpesvirus infected cells [40]. However knock down of either vFLIP or
vIRF3 expression in PELs sensitizes or induces apoptosis in these cells, so establishing lines
deficient in either of these may not be possible [18,30]. Such a question may be best addressed
by making viruses lacking either or both of these genes, using these to infect B cell lines which
are known to support virus expression of vIRF3, such as BJAB or primary B cells [14,41], and
then assess apoptotic sensitivity of these cells. Nevertheless, inhibiting function of either of
these may be sufficient then to allow improved control by immune effectors. Thus even though
AZT only inhibited vIRF3 function in the BJAB model, inhibition mediated by AZT over
vIRF3 in PELs may be sufficient to induce their sensitization to CD4+ T cell control.
Recently AZT has been used successfully with valganciclovir in an MCD setting where
these prodrugs are thought to be phosphorylated to toxic compounds by KSHVs lytic cycle
expressed thymidine kinase (ORF21) and phosphotransferase (ORF36) respectively[42].
Infected B lymphocytes within MCD lesions also express vIRF3 [10] and potentially AZT may
be inhibiting this proteins function, allowing better targeting by KSHV-specific CD4+ T cells.
Important in this context is that MCD patients, who are usually co-infected with HIV, have
relatively preserved immune competence in terms of CD4+ T cell numbers [42,43], although
no studies have so far examined KSHV-specific CD4+ T cell immunity in this patient group.
Correlating KSHV-specific CD4+ T cell responses with patient outcome upon AZT treatment
would help give an understanding of whether this drug and immune effector combination is
capable of controlling KSHV-infected cells in this group. Additionally, little is known as to
when vIRF3 is expressed in vivo, outside of cases of MCD and PEL. However as the gene
appears to be expressed in infected B lymphocytes [13,14,41] it would seem likely that it is
expressed during the establishment and maintenance of the latent KSHV reservoir in B lym-
phocytes. Potentially then, AZT treatment may help make infected B lymphocytes within the
latent reservoir more susceptible to T cell control. However our studies using the BJAB-vIRF3
transduced cells indicates that a concentration of 5 μg/ml AZT is required to inhibit vIRF3
function which would likely exceed plasma levels attained after a standard oral dose of 200 mg
of AZT that results in plasma AZT levels of 0.9–2.9 μg/ml [44]. To attain sufficient levels it
may be necessary to use high doses like those used in the above MCD setting of multiple oral
doses of 600 mg of AZT [42]. Nevertheless our studies suggest that interfering with vIRF3
function may help restore the virus-host balance.
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Materials and Methods
Cell lines and outgrowth assays
CD4+ T cell clones were established in a previous study [16] and their characteristics are
shown in Table 1. An additional specificity was included which recognized the HLA-DQ0601
presented vCyclin encoded peptide TFQQSLTSHMRKLLG. PEL cells were maintained in
RPMI-1640 (Sigma-Aldrich) with 10% fetal calf serum (FCS) (LifeTechnologies). PELs used in
outgrowth assays were VG-1 (a kind gift from Prof Christian Brander, IrsiCaixa AIDS
Research Institute–HIVACAT, Barcelona, Spain [45]), BCBL-1 (NIH AIDS Reagent Program,
catalogue number 3233, [46]) and JSC-1 (American Type Culture Collection, catalogue num-
ber CRL-2769, [47]). Outgrowth assays were performed by seeding doubling dilutions of tripli-
cate PEL cell cultures in 96 well plates, ranging from concentrations of 10 000 to 1250 cells per
well. PEL cultures had 10 000 CD4+ T cells added and assays were conducted in the presence
or absence of 10 μg/ml AZT (Sigma-Aldrich). Cultures were incubated for 10 days, after which
cell outgrowth identity was determined by staining cells with antibodies specific to CD138 or
CD4 (Biolegend). Stained cells were analyzed on an Accuri C6 flow cytometer (BD Biosci-
ences) and data analyzed using Flowjo (Treestar). Outgrowth assays were scored as the mini-
mal number of PELs seeded to overgrow T cells, as defined by there being an equal or greater
frequency of PEL cells compared to T cells at the end of the assay. Surface MHC class II expres-
sion on PEL lines was measured by staining with antibodies specific to HLA-DR (L243, Biole-
gend) and analyzing by flow cytometry.
qRT-PCR detection of Fas-ligand, TRAIL and KSHV transcripts
CD4+ T cell clones were activated by stimulation with peptide-epitope sensitized Epstein-Barr
virus-transformed B cells for five hours, RNA extracted and cDNA synthesized as described
[14]. Fas-ligand and TRAIL transcript levels were assessed by Taqman Gene Expression Assays
(ThermoFisher) on 5 ng of cDNA as described by the manufacturer. Relative levels of tran-
scripts were determined by comparing to dilutions of cDNA prepared from peripheral blood
mononuclear cells (PBMC) activated with phorbol myristate acetate and ionomycin for 5
hours[24,25].
KSHV transcript levels were estimated on RNA extracted from PELs using validated
qRT-PCR assays as previously described [14].
Ethics statement
PBMC were collected from healthy donors after obtaining written informed consent to donate
samples and experiments were approved by the South Birmingham Research Ethics Commit-
tee (approval reference number 06/Q2707/300).
Production and characterization of lentiviruses
The KSHV latent genes vCyclin, vFLIP, Kaposin B, vIRF3 and vIL-6 were PCR amplified from
cDNA extracted from the BCBL-1 PEL, additionally Kaposin B was epitope tagged with the
influenza HA epitope. Sequence encoding LANA was excised from the BCBL-1 derived
BAC36 construct [48] and these genes and a control vector lacking an insert cloned individu-
ally into pENTR1a (ThermoFisher). Constructs were recombined into the lentiviral vector
pInducer 20[49], which expresses transgenes under the control of a tetracycline regulated pro-
moter and the resulting plasmid co-transfected with standard plasmids encoding lentiviral
packaging and envelope genes into 293T cells (American Type Culture Collection, catalogue
number CRL-3216). After 48 hours, supernatants were used to infect BJAB cells (a kind gift
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from Prof George Klein [50]) and transduced BJABs selected by culturing in RPMI-1640 10%
FCS supplemented with 200 μg/ml G418. Transgene expression was assessed by inducing
expression with 2 μg/ml doxycycline for 24 hours, then lysing cells for either western blot or
qRT-PCR analysis as previously described[14,16]. Blots were probed with antibodies specific
to LANA (clone LN-53, Advanced Biotechnologies), vCyclin (94B, Abcam), vFLIP (4C1)[51],
HA (3F10, Roche), vIRF3 (CM-A807, Abnova), vIL-6 (Abbiotec), and actin (AC-74, Sigma)
and these detected using an appropriate anti-species HRP-conjugated antibody, followed by
ECL detection (GE Healthcare).
Apoptosis assays
Transgene expression in BJAB cells was induced for 24 hours by addition of 2 μg/ml doxycy-
cline, after which 150 000 cells were incubated in 100 μl of media with the indicated concentra-
tions of either an agonistic anti-Fas antibody (CH11, Beckman-Coulter) or recombinant
TRAIL (Peprotech) for 48 hours. Cell death was estimated using an Annexin V-propidium
iodide apoptosis detection kit (eBioscience) and cells analyzed by flow cytometry.
Statistical analysis
Statistical comparisons between levels of cell death in apoptosis assays were performed using
the R statistical program (v 3.0.2, R Development Core Team, http://www.R-project.org). So
that parametric statistical tests could be used we first assessed whether the data satisfied the
assumptions for use of these statistics namely that it was normally distributed using the Sha-
piro-Wilk test, and was homoscedastic using Levene’s test. To identify whether there were var-
iation in mean levels of cell death between groups, these were tested by one way ANOVA and
groups which differed were identified by post-hoc testing with Tukey’s Honest Significant Dif-
ference test.
Supporting Information
S1 Fig. KSHV gene transcript levels and proliferation of PELs treated with 10 μg/ml AZT.
A. RNA was extracted from parallel cultures of PELs either untreated or treated with 10 μg/ml
AZT. cDNA was subjected to qRT-PCR analysis for either the tricistronic LANA-vCyclin-
vFLIP, bicistronic vCyclin-vFLIP, monocistronic vFLIP, vIL-6, vIRF3, ORF50 and GAPDH
transcripts. Transcript levels are expressed relative to GAPDH abundance. Error bars repre-
sent standard error of the mean. B. PELs were seeded in 96 well U bottom plates in replicates
of 10 000 cells in 200 μl of media supplemented with or without 10 μg/ml AZT. Cells were
counted over a seven day period and representative results of one of two assays are shown.
Error bars indicate standard error of the mean.
(TIF)
S2 Fig. PEL outgrowth assays conducted using KSHV-specific CD4+ T cells pre-treated
with AZT. A. VG-1 PELs treated with 10 μg/ml AZT or not were seeded in triplicate cultures
at doubling dilutions from 104 cells per well to 1 250 cells per well. To these, 104 MHC-
matched LAP/LRS -specific CD4+ T cells, either clone 112 or clone 146 were added, or mis-
matched CD4+ T cell clones were added, namely clone 29 or clone 24. In parallel, cultures
were established which used T cell clones which had been pre-treated with 10 μg/ml AZT for
four days. Where indicated AZT was added to a final concentration of 10 μg/ml in the cultures.
Cell mixtures were allowed to grow for 10 days after which cell outgrowth was scored. Results
are expressed as the minimum number of PELs seeded which successfully outgrew the T cells
and the dashed line represents the number of AZT treated PELs seeded in the absence of T
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cells to achieve outgrowth. Black arrowheads indicate greater than 104 PELs were required to
outgrow the T cells. B. Outgrowth assays were set up as in A but using BCBL-1 cells which
were challenged with TFQ-specific CD4+ T cell clones 1 or 2. Results shown are representative
of one of two assays.
(TIF)
S3 Fig. Proliferation of BJAB cells treated with 10 μg/ml AZT. BJAB cells transduced with
the control lentivirus were seeded in 96 well U bottom plates in replicates of 10 000 cells in
200 μl of media supplemented with or without 10 μg/ml AZT. Cells were counted over a seven
day period and representative results of one of two assays are shown. Error bars indicate stan-
dard error of the mean.
(TIF)
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